

CLAIMS

1. A oncolytic herpes simplex virus (HSV) comprising a recombinant nucleic acid comprising:
 - i) a first nucleic acid sequence encoding a polypeptide comprising a first domain specific for an antigen expressed on an effector cell and a second domain that binds to an antigen expressed on a target cell, wherein the antigen expressed on the effector cell is CD3 and wherein the antigen expressed on the target cell is PDL1 or CD47; and
 - ii) a second nucleic acid sequence encoding an immune modulator polypeptide selected from the group consisting of a cytokine, a costimulatory molecule, an immune checkpoint polypeptide, an anti-angiogenesis factor, and a matrix metalloprotease (MMP).
2. The oncolytic HSV of claim 1, wherein the first and second nucleic acid sequences are expressed from a single promoter sequence present in the recombinant nucleic acid.
3. The oncolytic HSV of claim 1, wherein the first and second nucleic acids have a size of 7.2-38kb.
4. The oncolytic HSV of claim 1, wherein the HSV is HSV-1.
5. The oncolytic HSV of claim 1, wherein the immune modulator polypeptide is a cytokine selected from IL-15, IL-12, and CXCL10.
6. The oncolytic HSV of claim 1, wherein one or more of the HSV glycoproteins are modified to alter the tropism of the oncolytic HSV.